|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017638,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0205195,
umls-concept:C0297960,
umls-concept:C0441655,
umls-concept:C0870432,
umls-concept:C0906802,
umls-concept:C0935987,
umls-concept:C0935989,
umls-concept:C1328655,
umls-concept:C1515655,
umls-concept:C1517004,
umls-concept:C1555465,
umls-concept:C1705417,
umls-concept:C2348461,
umls-concept:C2349975
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-2-21
|
|
pubmed:abstractText |
The microtubule-stabilizing agent patupilone (epothilone B, EPO906) and the tyrosine kinase inhibitor imatinib (STI571, Glivec) which primarily inhibits Bcr-Abl, PDGF and c-Kit tyrosine kinase receptors, were combined in vivo to determine if any interaction would occur with respect to antitumour effect and tolerability using rat C6 glioma xenografted into nude mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
307-17
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15723258-Animals,
pubmed-meshheading:15723258-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15723258-Cell Line, Tumor,
pubmed-meshheading:15723258-Dose-Response Relationship, Drug,
pubmed-meshheading:15723258-Epothilones,
pubmed-meshheading:15723258-Glioma,
pubmed-meshheading:15723258-Mice,
pubmed-meshheading:15723258-Mice, Inbred BALB C,
pubmed-meshheading:15723258-Mice, Nude,
pubmed-meshheading:15723258-Neoplasm Transplantation,
pubmed-meshheading:15723258-Piperazines,
pubmed-meshheading:15723258-Pyrimidines,
pubmed-meshheading:15723258-Rats
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
|
|
pubmed:affiliation |
Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
